Kenneth Kalunian, MD
Rheumatology · San Diego, CANPI 1346269990
Payments from drug & device makers
Across 331 payments — averaging $4145.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$288K
- UCB SA$267K
- Amgen$192K
- Pfizer$187K
- AbbVie$118K
- AstraZeneca$71K
- plus $249K from 28 others
Across 18 payments — averaging $1473.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$9K
- Genentech, Inc.$8K
- Eli Lilly$6K
- AbbVie$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $288,046 |
| UCB SA | 25 | $267,144 |
| Amgen(2 entities) | 11 | $191,969 |
| Pfizer | 37 | $186,747 |
| AbbVie | 18 | $118,461 |
| AstraZeneca(2 entities) | 26 | $71,109 |
| Gilead | 15 | $40,824 |
| GSK | 29 | $36,768 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $29,954 |
| Astrazeneca UK Limited | 8 | $18,649 |
| E.r. Squibb & Sons, L.L.C. | 22 | $18,361 |
| Eli Lilly | 22 | $18,040 |
| Genentech, Inc. | 16 | $15,875 |
| Aurinia Pharma U.S., Inc. | 17 | $10,779 |
| Bristol Myers Squibb | 2 | $9,506 |
| F. Hoffmann-la Roche AG | 7 | $9,210 |
| Sanofi US Services Inc. | 9 | $9,144 |
| Biogen | 10 | $6,477 |
| Ablynx NV | 3 | $3,396 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $3,360 |
| Merck Healthcare Kgaa | 2 | $2,669 |
| Pacira Therapeutics, Inc. | 2 | $2,550 |
| Janssen Research & Development, LLC | 3 | $2,458 |
| Boehringer Ingelheim | 1 | $1,980 |
| Merck Kgaa | 2 | $1,904 |
| ANI Pharmaceuticals, Inc. | 1 | $1,488 |
| Merck | 1 | $1,300 |
| Idorsia Pharmaceuticals US Inc | 1 | $1,250 |
| Beigene USA, Inc. | 1 | $1,000 |
| Veloxis Pharmaceuticals, Inc. | 1 | $675 |
| Vertex | 1 | $500 |
| Janssen Scientific Affairs, LLC | 3 | $357 |
| UCB, Inc. | 2 | $98 |
| Lilly USA, LLC | 1 | $1 |
How this compares
$1,372,048 in reported general payments places this provider in the 95th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in San Diego
- Ara DikranianSan Diego$2.6M
- Arthur MabaquiaoSan Diego$1.6M
- Samy MetyasCovina$12.9M
- Christine ThaiHuntington Beach$8.5M
- Tien-I SuWhittier$8.4M
- Eric LeeUpland$6.9M
- Orrin TroumSanta Monica$6.9M
- Shirley PangFullerton$5.7M
- William RobinsonStanford$5.1M
- Dan laTujunga$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.